Deal lets Volcano add PAD device to its portfolio

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Volcano will pay up to $130 million to acquire AtheroMed, giving Volcano access to a recently FDA-approved treatment for peripheral artery disease (PAD).

In January, AtheroMed received FDA clearance for its Phoenix Atherectomy System, a low-profile primary therapy for treating PAD. The technology uses an over-the wire system with a rotating, front-cutting element at the distal tip of a catheter that shaves diseased material into the catheter. The debulked material is continuously removed through an internal mechanism.

San Diego-based Volcano announced that it will pay $115 million in cash and an additional $15 million contingent on FDA approval of another Phoenix device before Nov. 15, 2014. Volcano is targeting the end of 2014 for a limited market release of Phoenix and a full market release in early 2015.

Manufacturing will shift from AtheroMed’s site in Menlo Park, Calif., to Volcano’s facility in Costa Rica in late 2015.

The acquisition is expected to be completed this quarter.

Candace Stuart, Contributor

Related Content

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors
Advancing AI for vascular surgery will require a commitment to data integrity
Industry concerns over paclitaxel-coated devices may have put PAD patients at risk
Genetic predisposition to depression increases CVD risk in women, but not men
Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups
IVUS-guided PCI reduces risks in patients with diabetes

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.